The decision comes after tominersen did no better than placebo in a Phase 2 trial with patients in the earliest stages of the disease.
After more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen.
The decision comes after …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a…
HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage…
L’obiettivo è verificare se il medicinale sia in grado di ritardare o prevenire l’insorgenza dei sintomi cognitivi tipici della…
Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy…
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the…
